KennethHShainMD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Associate Member Moffitt Cancer Center

Overview of Dr. Shain

Dr. Kenneth Shain is a hematologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of South Florida Morsani College of Medicine and has been in practice 11 years. He is one of 45 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Hematology. He has more than 90 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
# Mrc
Tampa, FL 33612
Book by Phone+1(563) 362-9147

Fax+1 813-745-6817

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2008 - 2011
University of South Florida MorsaniResidency, Internal Medicine, 2006 - 2008
University of South Florida College of MedicineClass of 2006

Certifications & Licensure

FL State Medical License 2010 - 2026

Clinical Trials

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2009 Jun 01
Completed
Phase 1, Phase 2
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
Completed
Phase 2
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2012 Feb 01
Unknown status
Phase 1, Phase 2
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma Start of enrollment: 2014 Sep 23
Completed
Phase 1, Phase 2
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma Start of enrollment: 2020 Feb 11
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
Ajai Chari, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves
Blood Cancer Journal. 2024-07-08
381 citations
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach, Douglas W. Sborov, Brandi Reeves
Blood. 2020-08-20
21 citations
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
Michael G. Fradley, John D. Groarke, Jacob P. Laubach, Melissa Alsina, Daniel J. Lenihan
British Journal of Haematology. 2018-01-01

Abstracts/Posters

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
Kenneth H. Shain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Kenneth H. Shain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Composition of Immune Subpopulations Influence Multiple Myeloma Disease Progression
Kenneth H. Shain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis...
Kenneth H. Shain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeu...
Kenneth H. Shain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma
Kenneth H. Shain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker
Kenneth H. Shain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Pharmacodynamical Modeling of Two-Way Synergistic Effect for High-Throughput Drug Combination Screening in an Ex Vivo Reconstruction of Bone Marrow Using Primary Multi...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018